Effect of Dapagliflozin in Patients with Diabetes and Heart Failure with Mildly Reduced or Preserved Ejection Fraction According to Background Glucose-Lowering Therapy: A Pre-Specified Analysis of the DELIVER Trial

Mats Christian Højbjerg Lassen(University of Copenhagen), Muthiah Vaduganathan(Brigham and Women's Hospital), Kieran F. Docherty(British Heart Foundation), Brian Claggett(National Heart Lung and Blood Institute), Anna Maria Langkilde(AstraZeneca (Sweden)), Adrian F. Hernandez(Duke University), Pardeep S. Jhund(Copenhagen University Hospital), John W. Ostrominski(Brigham and Women's Hospital), John J.V. McMurray(University of Glasgow), Magnus Petersson(Stockholm University), Rudolf A. de Boer(Erasmus MC), Felipe A. Martínez(Universidad Nacional de Córdoba), Mikhail Kosiborod(AstraZeneca (Brazil)), Scott D. Solomon(Brigham and Women's Hospital), Ian J. Kulac(Brigham and Women's Hospital), Carolyn S.P. Lam(University of Glasgow), Silvio E. Inzucchi(Yale University), Akshay S. Desai(Brigham and Women's Hospital), Sanjiv J. Shah(Northwestern University)
European Journal of Heart Failure
May 15, 2024
Cited by 11


Related Papers